Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Daiichi Sankyo 2
Trials & R&D · first seen 13h ago, updated 13h ago

Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare

1 outlet Eli Lilly

InnoCare, which already has three approved therapies, describes itself as a biopharma focusing on cancer and autoimmune disease treatments.

Summary from Pharmaceutical Technology.

Coverage 1 article · 1 outlet

  1. Pharmaceutical Technology
    Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare